BIOXCEL THERAPEUTICS, INC. INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies BTAI Investors of a Class Action Lawsuit and Upcoming Deadline
03 août 2023 09h00 HE
|
Kaplan Fox & Kilsheimer LLP
NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of persons and entities that purchased or acquired securities...
The Future of Oral Therapeutics: Global Macromolecule Formulation Market Estimated at USD 29.5 million by 2033: Persistence Market Research
02 août 2023 13h27 HE
|
Persistence Market Research
New York, Aug. 02, 2023 (GLOBE NEWSWIRE) -- The global oral macromolecule formulation market is expected to grow at a CAGR of 5.0% from 2022 to 2033. The global oral macromolecule formulation market...
Syneos Health Stockholders Approve Agreement with Private Investment Consortium
02 août 2023 08h47 HE
|
Syneos Health, Inc.
MORRISVILLE, N.C., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (“Syneos Health” or the “Company”), a leading fully integrated biopharmaceutical solutions organization, today...
Affimed Announces an ASCO Breakthrough Poster Presentation with Clinical Data of AFM24 in Combination with NKGen Biotech’s SNK01 NK Cells
31 juil. 2023 17h05 HE
|
Affimed N.V.
Stable disease was observed in three out of seven heavily pretreated patientsNo dose-limiting toxicities or unexpected toxicities were observed HEIDELBERG, Germany, July 31, 2023 (GLOBE NEWSWIRE)...
Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites
28 juil. 2023 08h00 HE
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company...
PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301
24 juil. 2023 08h00 HE
|
PaxMedica, Inc.
The study’s primary endpoint was reached and demonstrated statistically significant and clinically meaningful resultsThese results pave the way for filing an NDA for the use of PAX-101 (intravenous...
Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement
24 juil. 2023 07h30 HE
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage...
Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in the Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas (DMGs)
10 juil. 2023 08h00 HE
|
Biodexa Pharmaceuticals PLC
10 July 2023 Biodexa Ltd(“Biodexa” or the “Company”) Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in theTreatment of Children with Newly Diagnosed Diffuse Midline Gliomas...
Results of Appeal of Delisting Determination
06 juil. 2023 16h30 HE
|
Biodexa Pharmaceuticals PLC
6 July 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Results of Appeal of Delisting Determination Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical...
Publication of Manuscript from the PNOC015 (a.k.a. MTD-201) Study in Patients with Diffuse Midline Glioma (DMG)
06 juil. 2023 08h15 HE
|
Biodexa Pharmaceuticals PLC
6 July 2023 Biodexa Ltd(“Biodexa” or the “Company”) Publication of Manuscript from the PNOC015 (a.k.a. MTD-201) Study in Patients with Diffuse Midline Glioma (DMG) Biodexa Pharmaceuticals PLC...